The facility, located in Anagni, Italty, is an oral solid, biologics and sterile product manufacturing and packaging building. It primarily serves as Bristol-Myers’ launch facility for new medicines.
The companies said the deal should wrap up by the end of 2019.
“We believe that the sale to Catalent will continue the vital role the Anagni facility plays for its workforce, the community and patients,” Lou Schmukler, president, global product development and supply, Bristol-Myers Squibb, said. “This marks an important step in the ongoing evolution of our manufacturing network to support the company’s innovative product portfolio. Bristol-Myers Squibb has a long history in Italy, and we intend to maintain a continued strategic presence in Italy, which is critical for our ability to deliver transformational medicines to patients.”
Once the deal has closed, Catalent plans to continue manufacturing Bristol-Myers’ current product portfolio at the site. The facility will also provide Catalent biologics customers with access to advanced sterile drug product fill/finish and packaging capacity and Europe.
“The addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply.” He added, “Bristol-Myers Squibb has invested in the facility to create a center of excellence for new product launches with a robust quality and delivery record, and an employee base who shares Catalent’s operational excellence and patient focus,”Alessandro Maselli, president and chief operating officer, Catalent, said.
William Blair & Co. served as the financial advisor to Bristol-Myers.
Financial terms were not disclosed.